CRISPR Base Editing Lowers Cholesterol by 55% in Phase 2 Trial: Verve Therapeutics One-Time Treatment 2026

What Are the Phase 2 Results for CRISPR Cholesterol Treatment?

Verve Therapeutics presented Phase 2 data from the Heart-2 trial at the American College of Cardiology Annual Scientific Session on March 12, 2026, demonstrating that their CRISPR base editing therapy VERVE-102 reduced low-density lipoprotein (LDL) cholesterol by a mean of 55% at 6 months post-infusion. The trial enrolled 67 adults with heterozygous familial hypercholesterolemia (HeFH) who had LDL levels above 100 mg/dL despite maximally tolerated statin therapy. Participants receiving the highest dose tier achieved LDL reductions of up to 62%, with PCSK9 protein levels dropping by 81%.

Unlike existing PCSK9 inhibitors such as evolocumab and alirocumab, which require injections every 2-4 weeks, VERVE-102 uses lipid nanoparticles to deliver an adenine base editor directly to hepatocytes, making a permanent single-letter change in the PCSK9 gene. This effectively silences production of the PCSK9 protein, which normally prevents LDL receptors from clearing cholesterol from the blood. The therapy was administered as a one-time 90-minute intravenous infusion, with the most common side effects being transient mild elevations in liver enzymes observed in 12% of participants, all resolving within two weeks.

How Does Base Editing Differ From Traditional CRISPR Gene Therapy?

Traditional CRISPR-Cas9 technology works by cutting both strands of the DNA double helix at a target site, relying on the cell's own repair mechanisms to introduce the desired change. This approach carries a risk of insertions, deletions, and chromosomal rearrangements. Base editing, developed by David Liu's laboratory at the Broad Institute, instead uses a modified Cas9 protein fused to a deaminase enzyme that chemically converts one DNA base to another — in this case, adenine to guanine — without ever breaking the DNA backbone. Published data in Nature Medicine (2026) showed that VERVE-102's off-target editing rate was below 0.1% across the entire genome.

The clinical significance extends beyond familial hypercholesterolemia. An estimated 1 in 250 people worldwide carry mutations causing HeFH, yet fewer than 10% are adequately treated with current therapies. The World Health Organization estimates that elevated LDL cholesterol contributes to 4.4 million deaths annually from ischemic heart disease. If the Phase 3 Heart-3 trial, expected to begin enrollment in Q3 2026 with 450 participants, confirms these results, VERVE-102 could fundamentally change cardiovascular prevention by replacing lifelong daily or biweekly medications with a single treatment.

What Does This Mean for Patients With High Cholesterol?

For the estimated 31 million people in the United States living with familial hypercholesterolemia, medication adherence remains a major barrier to achieving target LDL levels. Studies show that approximately 50% of patients prescribed statins discontinue them within one year, and only 30% of HeFH patients reach their LDL goal of below 70 mg/dL. A permanent, one-time treatment that eliminates the need for ongoing medication could dramatically improve cardiovascular outcomes in this population. Health economic modeling presented alongside the trial data estimated that VERVE-102 could be cost-effective at a price point of up to $250,000 when accounting for lifetime savings on medications, monitoring, and cardiovascular event prevention.

However, experts caution that long-term safety data beyond 6 months are still needed, and the durability of the LDL reduction must be confirmed over years, not months. Dr. Sekar Kathiresan, CEO of Verve Therapeutics, noted that non-human primate studies showed sustained PCSK9 reduction for over 3 years. The FDA has granted VERVE-102 Breakthrough Therapy designation, which could accelerate the regulatory review timeline. Cardiologists emphasize that even if approved, the therapy would initially be targeted at the highest-risk HeFH patients rather than the general population with elevated cholesterol.